CytoGenix

CytoGenix, Inc. is a biopharmaceutical company that develops and markets innovative compounds and services based on its proprietary gene

CytoGenix, Inc. is a biopharmaceutical company that develops and markets innovative compounds and services based on its proprietary gene regulating and DNA production technologies. CytoGenix has products in pre-clinical development including an antimicrobial compound, DNA vaccines and anti-herpes and anti-inflammatory topical creams. The Company has developed a cell free process for synthesizing DNA which it uses for its own products as well as marketing specific compounds to other companies. CytoGenix, Inc. currently has 11 granted patents (1 US, 1 China, 9 Europe) covering our basic ssDNA expression technology, with one additional allowance (India) pending. We have an additional 11 applications pending in various countries which are currently progressing through the normal prosecution process. The Company actively collaborates with numerous academic centers of excellence, government agencies and biotechnology industry partners. Cytogenix, Inc. is publicly traded under the symbol CYGX on the NASDAQ Over the Counter Bulletin Board.